Radiopharmaceutical firm DraxImage has decided to realign its research and development activities, a process that will include a new effort to develop generic radiopharmaceuticals.
Over the next one to three years, the subsidiary of Mississauga, Ontario-based Draxis Health said it would be focusing on developing its own versions of a series of currently marketed radiopharmaceutical and imaging products whose patents have expired or are close to expiring. Such products could include sestamibi and a production and distribution of a next-generation version of a technetium generator, Draximage said.
DraxImage is also accelerating its efforts to obtain registrations in European markets for five of its existing products that are currently approved and sold in Canada or the U.S.
DraxImage said that its highest priority over the three- to five-year horizon is the continued development of its Infecton imaging radiopharmaceutical for imaging infections. Additional medium-term development will focus on new radiopharmaceuticals and nonradioactive imaging products to round out its current product portfolio and leverage existing production processes and technologies, according to the firm.
For the long-term, DraxImage has initiated a program to establish strategic partnerships with biopharmaceutical companies and academic institutions to identify innovative products and technologies.
DraxImage has also decided not to conduct significant further work on developing its Fibrimage radiopharmaceutical for deep venous thrombosis indications. The company said it will explore other potential opportunities for Fibrimage, however.
By AuntMinnie.com staff writers
March 28, 2006
Related Reading
Draxis shows 2005 revenue growth, February 10, 2006
Draxis radiopharmaceutical approved, January 13, 2006
Draxis iodine kit gets FDA approval, November 22, 2005
Draxis Health lowers expectations, November 21, 2005
Temporary shutdown hurts Draxis Health’s Q3, November 3, 2005
Copyright © 2006 AuntMinnie.com
